Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases
Tatyana V. Masyuk, Brynn N. Radtke, Angela J. Stroope, Jesús M. Banales, Sergio A. Gradilone, Bing Huang, Anatoliy I. Masyuk, Marie C. Hogan, Vicente E. Torres, Nicholas F. LaRusso – 21 November 2012 – In polycystic liver (PLD) and kidney (PKD) diseases, increased cyclic adenosine monophosphate (cAMP) levels trigger hepatorenal cystogenesis. A reduction of the elevated cAMP by targeting somatostatin receptors (SSTRs) with octreotide (OCT; a somatostatin analog that preferentially binds to SSTR2) inhibits cyst growth.